ADAM17 and cardiac hypertrophy: Using a TACE inhibitor to increase tmTNF-α expression attenuated TAC-induced cardiac hypertrophy and inflammation, highlighting this molecule as a promising target for the treatment of pressure overload–induced cardiac hypertrophy.